FDA advisory committee votes 16-0 in favor of approving semaglutide

An FDA advisory committee voted unanimously, 16-0, on October 18, 2017, to recommend approval of once-weekly semaglutide as a treatment for type 2 diabetes.^[1] The vote was a key regulatory step before the FDA made its final decision on the drug.^[1]

Novo Nordisk had filed for regulatory approval of once-weekly semaglutide with the FDA on December 5, 2016, formally starting the review process.^[1] Less than two months after the advisory committee's unanimous vote, the FDA approved the drug on December 5, 2017, under the brand name Ozempic, for adults with type 2 diabetes.^[1]

Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by stimulating insulin secretion and lowering glucagon secretion when blood glucose is high.^[1] At the time of its 2017 approval, Ozempic injection was cleared as an add-on to diet and exercise to improve blood sugar control in adults with type 2 diabetes.^[1] The drug's approved uses have since expanded well beyond that original indication. Ozempic injection is now also indicated to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.^[1]

Ozempic injection comes with a boxed warning for thyroid C-cell tumors.^[1] Other warnings and precautions listed by the manufacturer include acute pancreatitis, complications of diabetic retinopathy, low blood sugar, acute kidney injury from volume depletion, serious gastrointestinal reactions, serious allergic reactions, acute gallbladder disease, and risk of pulmonary aspiration during general anesthesia or deep sedation.^[1] The most common side effects reported in at least 5% of patients treated with Ozempic injection are nausea, vomiting, diarrhea, abdominal pain, and constipation.^[1]

Why it matters for patients

This 2017 advisory committee vote marked one of the earliest regulatory milestones for semaglutide, the active ingredient that would later become the basis for several widely used drugs, including Ozempic, Wegovy, and Rybelsus.^[1] For patients today, the vote is a reminder that semaglutide's path to market began specifically as a diabetes treatment, not as a weight-loss drug. The weight-management version, Wegovy, was not approved until June 4, 2021, years after the original Ozempic approval.^[1]

The unanimous committee vote also reflects how semaglutide has since accumulated additional approved uses over time, including cardiovascular risk reduction and kidney disease indications that were not part of the original 2017 approval.^[1] Patients using semaglutide-based medications should be aware that the specific approved use, dosage form, and warnings can vary depending on the brand and formulation, since Novo Nordisk has released semaglutide under multiple brand names and dosage forms since 2017, including injections and tablets.^[1]

What happens next

After the October 18, 2017 advisory committee vote, the FDA approved Ozempic injection for type 2 diabetes on December 5, 2017.^[1] The sources provided do not detail the FDA's internal deliberations between the committee vote and the final approval decision, so the specific reasoning behind the agency's timing is not known from these materials. Semaglutide's approved uses and formulations continued to expand in the years that followed, according to the broader approval history, though those later developments fall outside the scope of the October 2017 committee vote itself.^[1]